Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Effective Collaboration - Team Research for Better Returns: -- Ignore unavailable to you. Want to Upgrade?

To: richardred who wrote (1574)	3/15/2013 12:50:08 PM
From: The Ox	Respond to of 8251

I glanced at OMPI earnings and they looked pretty good vs. expectations. Don't know the stock but put it on a watch list after your mention of it. Nice pop in the stock!

To: richardred who wrote (1574)	3/20/2013 8:49:12 AM
From: richardred	1 Recommendation Read Replies (3) \| Respond to of 8251

RE:OMPI- Mission accomplished Valeant to buy Obagi Medical for about $344 mln March 20 \| Wed Mar 20, 2013 8:12am EDT (Reuters) - Canadian drugmaker Valeant Pharmaceuticals International Inc said it would buy Obagi Medical Products Inc for about $344 million to boost its dermatology and aesthetics portfolio. The deal, at $19.75 per share in cash, is at a 28 percent premium to Obagi's Tuesday closing price. Obagi's board has unanimously approved the deal, Valeant said in a statement reuters.com